Otsuka Oral Tolvaptan NDA Carries August Goal For FDA Action
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's acceptance of Otsuka's NDA for the investigational V2-vasopressin receptor antagonist tolvaptan positions the drug to be the first oral product in the increasingly crowded vasopressin antagonist market